Home » Newsletters » BioWorld Science

BioWorld Science

June 19, 1997

View Archived Issues

Centocor sells infectious disease business

Targeted Genetics receives notice of patent allowance for gene delivery technology

Targets for antimigraine therapy: antiepileptic drugs in the treatment of migraine

RPR seeks FDA approval for DDAVP tablets for bed-wetting

Almotriptan: a novel antimigraine agent from Almirall

Preclinical profile of novel migraine abortive from BMS

Joint venture formed to market RenaGel

Preclinical studies reported for rizatriptan

Allelix to form Allelix Neuroscience following acquisition of Trophix

Preclinical and clinical studies indicate safety and efficacy of SB-209509/VML-251 for migraine

Promising results reported for Senetek's INVICORP for male erectile dysfunction

Eletriptan: a safe, effective and rapid antimigraine therapy

Sugen receives notices of allowance covering SU-101 for solid tumor treatment

In vitro antifungal activity of new echinocandin derivative

FDA clears American Biogenetic Sciences' fibrinogen test

Carbamate antifungal agents

New topical imidazole antifungal from Nihon Noyaku

Antifungal plant products

Trovafloxacin modulates the in vivo activity of antifungal agents

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...